ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Exits RNAi Therapeutics

by Lisa M. Jarvis
April 21, 2014 | APPEARED IN VOLUME 92, ISSUE 16

Novartis is shutting down its remaining RNAi drug discovery operations, a decision prompted by the ongoing difficulty in developing effective methods of formulating and delivering RNAi-based therapeutics. The company entered the field in 2005 through a broad partnership with Alnylam but in 2010 turned down an option to extend that collaboration. That pact gave Novartis the rights to 31 drug targets against which it could develop RNAi therapeutics. About 26 people in Cambridge, Mass., were focused on RNAi. Although the exit will cost at least some jobs, a Novartis spokesperson notes that a small team will be maintained and partnerships will be considered if technical issues are resolved.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment